The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era

Eschbach J. , Abdulhadi M. , Browne J. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989; 111: 992–1000.

Evans R. , Rader B. , Manninen D. Group CMECT. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263: 825–30.

Teruel J. , Marcen R. , Navarro-Antolin J. , Aguilera A. , Fernandez-Juarez G. , Ortuno J. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am Soc Nephrol 1996; 7: 140–4.

Ballal S. , Domoto D. , Polack D. , Marciulonis P. , Martin K. Androgens potentiate the effects of erythropoietin in the treatmtent of end-stage renal disease. Am J Kidney Dis 1991; 27: 29–33.

Derns J. , Rudnick M. , Cohen R. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37: 264–7.

Gaughan W. , Liss K. , Dunn S. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30: 495–500.

Dombros N. , Digenis G. , Soliman G. , Oreopoulos D. Anabolic steroids in the treatment of malnourished CAPD patients: A retrospective study. Perit Dial Int 1994; 14: 344–7.

Soliman G. , Oreopoulos D. Anabolic steroids and malnutrition in chronic renal failure. Perit Dial Int 1994; 14: 362–5.

Johansen K. , Mulligan K. , Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 1998; 281: 1275–81.

Shahidi N. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72–80.

Teruel J. , Marcen R. , Navarro J. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. Nephron 1995; 70: 282–6.

Naets J. , Wittek M. The mechanism of action of androgens on erythropoiesis. Annals of the New York Academy of Sciences 1968; 149: 366–76.

Meineke H. , Crafts R. Further observations on the mechanism by which androgens and growth hormone influence erythropoiesis. Annals of the New York Academy of Sciences 1968; 149: 298–307.

Gorshein D. , Murphy S. , Gardner F. Comparative study on the erythropoietic effects of androgens and their mode of action. J Appl Physiol 1973; 35: 376–8.

Neff M. , Goldberg J. , Slifkin R. A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 1981; 304: 871–5.

Doane B. , Fried W. , Schwartz F. Response of uremic patients to nandrolone decanoate. Arch Intern Med 1975; 135: 972–5.

Hendler E. , Goffinet J. , Ross S. , Longnecker R. , Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med 1974; 291: 1046–51.

Cattran D. , Fenton S. , Wilson D. , Oreopoulos D. , Shimizu A. , Richardson R. A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney Int 1977; 12: 430–7.

Williams J. , Stein J. , Ferris T. Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. Arch Intern Med 1974; 134: 289–93.

Teruel J. , Aguilera A. , Marcen R. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Scand J Urol Nephrol 1996; 30: 403–8.

Teruel J. , Aguilera A. , Acila C. , Ortuno J. Effects of androgen therapy on prostatic markers in hemodialyzed patients. Scand J Urol Nephrol 1996; 30: 129–31.

Teruel J. , Lasuncion M. , Rivera M. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997; 29: 569–75.